4 results about "Chondropathy" patented technology

The invention discloses an articular cartilage MRI (Magnetic Resonance Imaging) image intelligent enhancement and contrast optimization system, which belongs to the technical field of medical image processing and comprises a cartilage feature extraction module, a self-adaptive enhancement module, a contrast optimization module and a quality evaluation feedback module, the cartilage feature extraction module realizes cartilage region classification and structural analysis based on T2 relaxation time distribution features and multi-scale structure tensor features; the adaptive enhancement module performs differential enhancement according to the region type and the structural feature; the contrast optimization module realizes contrast dynamic optimization through nonlinear mapping and edge gradient adaptive adjustment; according to the articular cartilage MRI image display system and method, the display quality of the articular cartilage MRI image is remarkably improved, the cartilage display definition is improved by 73% or above compared with that of an original image, and a high-quality imaging basis is provided for accurate diagnosis of chondropathy.

Methods of using cell communication network factor 3 (CCN3) for the treatment of bone or cartilage disorders are provided. Also provided are methods of gene therapy, including methods of expressing CCN3 in vivo in an amount effective to promote new bone or cartilage growth. In addition, methods of screening for agonists, mimetics, and analogs of CCN3 are provided.

The present invention relates to a pharmaceutical composition in the form of a sterile and injectable dosage form comprising a controlled release dosage form comprising colchicine for use in the treatment of arthropathy, such as osteoarthritis, aggressive hand osteoarthritis and any other type of chondropathy, by intraarticular injection of said pharmaceutical composition into the joint, such as osteoarthritis, aggressive hand osteoarthritis, and any other type of chondropathy. The present invention relates to colchicine, in particular colchicine, and / or for the treatment of pain-related arthropathy, and / or for the protection of joints, bones and / or cartilages, in which 80% by weight of colchicine is released for more than one month, and in which colchicine is present in a concentration of 1 to 27.5 mg per mL of sterile and injectable dosage, and / or for the treatment of pain-related arthropathy, and / or for the protection of joints, bones and / or cartilages. The invention also relates to a sterile and injectable pharmaceutical composition comprising a controlled release dosage form containing colchicine, which has a suitable in vitro dissolution characteristic. The invention also relates to a formulation in powder form and to a pharmaceutical composition in sterile and injectable dosage form form suitable for intra-articular injection comprising colchicine, in particulate form comprising a polymer matrix, and to a related kit or article of manufacture.

The application discloses a traditional Chinese medicine composition for preventing and treating knee osteoarthritis and application thereof, and relates to the technical field of knee osteoarthritis treatment. The traditional Chinese medicine composition is Sanqiang Decoction which is composed of the following raw materials in parts by weight: Eucommia ulmoides leaves 90-150 parts, Chaenomeles speciosa 60-120 parts, Astragalus membranaceus 90-150 parts, Gastrodia elata 35-65 parts, Dendrobium 35-65 parts, Pueraria lobata 90-150 parts, Curcuma longa 35-65 parts, Persicae Semen 35-65 parts, Coix seed 60-120 parts, Fructus Corni 75-125 parts and calcium gluconate 9-15 parts. The Sanqiang Decoction in the application can improve the pathological state of cartilage and the microstructure parameters of subchondral bone of knee osteoarthritis, improve the antioxidant stress capacity, and improve the quadriceps atrophy caused by knee osteoarthritis, and has good pharmacological effects. The mechanism is related to the activation of TGF-beta 1 / Smad3, Nrf2-Keap1 and PI3K / AKT / FOXO1 pathways.